Abstract
The purpose of this study is to investigate the relationship between nestin expression and clinicopathological characteristics, immunohistochemical markers and to determine the prognostic impact of nestin expression in breast cancer so as to lay a foundation for the treatment of breast cancer. A total of 109 patients who were histologically diagnosed with breast cancer and underwent radical operations from January 2006 to September 2007 in China Medical University were enrolled in the study. Nestin protein expression was evaluated by immunohistochemistry. The relationship between nestin and other parameters was analyzed by using chi-square test and Fisher’s exact test. Nestin expression was observed in 37.6 % (41/109) of cases. There were no significant differences between the age of >40 and ≤40 years group in terms of nestin expression (39.8 vs 18.2 %; P = 0.161). The rate of nestin expression between those with and without lymph node metastasis was not significantly different (X 2 = 0.086; P = 0.769). The 5-year survival rates of the patients with nestin expression and those without were 34.1 % (14/41) and 55.9 % (38/68), respectively (P = 0.028). Overall, triple-negative breast cancers had higher expression rates than other cancers (54.1 vs 29.2 %; P = 0.011). Nestin expression rate in ER- and PR-negative tumors was found to be significantly higher than cases that were ER- and PR-positive (P = 0.011 and P = 0.036, respectively). However, it was not found that HER2 expression was related to nestin expression (P = 0.120). These results suggest that the expression of nestin might play an important role in the prognosis of breast carcinoma, especially in the triple-negative subgroups.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Desantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA Cancer J Clin. 2011;61:409–18.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
Briest S, Stearns V. Tamoxifen metabolism and its effect on endocrine treatment of breast cancer. Clin Adv Hematol Oncol. 2009;7(3):185–92.
Weigelt B, Mackay A, A'hern R, Natrajan R, Tan DS, Dowsett M, et al. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol. 2010;11(4):339–49.
Tropepe V, Alton K, Sachewsky N, Cheng V, Kuo C, Morshead CM. Neurogenic potential of isolated precursor cells from early post-gastrula somitic tissue. Stem Cells Dev. 2009;18(10):1533–42.
Sahlgren CM, Pallari HM, He T, Chou YH, Goldman RD, Eriksson JE. A nestin scaffold links Cdk5/p35 signaling to oxidant-induced cell death. EMBO J. 2006;25(20):4808–19.
Parry S, Savage K, Marchiò C, Reis-Filho JS. Nestin is expressed in basal-like and triple negative breast cancers. J Clin Pathol. 2008;61(9):1548–50.
Piras F, Ionta MT, Lai S, Perra MT, Atzori F, Minerba L, et al. Nestin expression associates with poor prognosis and triple negative phenotype in locally advanced (T4) breast cancer. Eur J Histochem. 2011;55(39):215–20.
Ishiwata T, Matsuda Y, Naito Z. Nestin in gastrointestinal and other cancers: effects on cells and tumor angiogenesis. World J Gastroenterol. 2011;17(4):409–18.
Makino S. The role of tumor stem-cells in regrowth of the tumor following drastic applications. Acta Unio Int Contra Cancrum. 1959;15 Suppl 1:196–98.
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444:756–60.
Eramo A, Ricci-Vitiani L, Zeuner A, Pallini R, Lotti F, Sette G, et al. Chemotherapy resistance of glioblastoma stem cells. Cell Death Different. 2006;13(7):1238–41.
Lobo NA, Shimono Y, Qian D, Clarke MF. The biology of cancer stem cells. Annu Rev Cell Dev Biol. 2007;23:675–99.
Hoffman RM. The potential of nestin-expressing hair follicle stem cells in regenerative medicine. Expert Opin Biol Ther. 2007;7:289–91.
Kolar Z, Ehrmann Jr J, Turashvili G, Bouchal J, Mokry J. A novel myoepithelial/progenitor cell marker in the breast? Virchows Arch. 2007;450:607–9.
Yang XH, Wu QL, Yu XB, Xu CX, Ma BF, Zhang XM, et al. Nestin expression in different tumours and its relevance to malignant grade. J Clin Pathol. 2008;6(1):467–73.
Liu C, Chen B, Zhu J, Zhang R, Yao F, Jin F, et al. Clinical implications for nestin protein expression in breast cancer. Cancer Sci. 2010;101(3):815–19.
Li H, Cherukuri P, Li N, Cowling V, Spinella M, Cole M, et al. Nestin is expressed in the basal/myoepithelial layer of the mammary gland and is a selective marker of basal epithelial breast tumors. Cancer Res. 2007;67:501–10.
Zhu J. The relationship between nestin expression and clinicopathological factors. Liaoning:China Medical University, 2010.
Acknowledgments
This study was supported by the national natural science funds (no. 81172047 and no. 81102029).
Conflicts of interest
None
Author information
Authors and Affiliations
Corresponding authors
Additional information
Ningning Gao and Hong Xu were co-first authors
Rights and permissions
About this article
Cite this article
Gao, N., Xu, H., Liu, C. et al. Nestin: predicting specific survival factors for breast cancer. Tumor Biol. 35, 1751–1755 (2014). https://doi.org/10.1007/s13277-013-1548-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13277-013-1548-7